CTOs on the Move

SameSky Health

www.sameskyhealth.com

 
SameSky Health is a developer of a patient engagement platform intended to connect payers, providers, and health systems with multi-cultural Medicare patient populations. The company`s platform addresses the needs of clients with multi-cultural populations through web and application-based integrated services including multi-channel messaging, care navigation, and data insights and consultancy. It was formerly known as ConsejoSano and changed it`s name to SameSky Health. The company was founded in 2017 and is based in North Hollywood, California.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sameskyhealth.com
  • 5200 Lankershim Boulevard Suite 310
    North Hollywood, CA USA 91601
  • Phone: 855.735.6726

Executives

Name Title Contact Details
Josh Siegel
Chief Technology Officer Profile

Funding

SameSky Health raised $17M on 12/15/2020

Similar Companies

American HealthChoice

American HealthChoice, Inc. is a Flower Mound, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PTS Inc

PTS Inc is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Organizers

Organizers is a Monrovia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.